Thomas H. Stevens

Array ( [id] => 11436119 [patent_doc_number] => 20170037140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-09 [patent_title] => 'COMBINATION THERAPIES FOR B-CELL LYMPHOMAS COMPRISING ADMINISTRATION OF ANTI-CD20 ANTIBODY' [patent_app_type] => utility [patent_app_number] => 15/334235 [patent_app_country] => US [patent_app_date] => 2016-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 17934 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15334235 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11114932 [patent_doc_number] => 20160311906 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-27 [patent_title] => 'MODULATION OF NKG2D' [patent_app_type] => utility [patent_app_number] => 15/081305 [patent_app_country] => US [patent_app_date] => 2016-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 23866 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15081305 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11092374 [patent_doc_number] => 20160289342 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-10-06 [patent_title] => 'ANTI-CD20- / ANTI-BAFF BISPECIFIC ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/079184 [patent_app_country] => US [patent_app_date] => 2016-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13362 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15079184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11074286 [patent_doc_number] => 20160271249 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-22 [patent_title] => 'COMBINATION OF AURORA KINASE INHIBITORS AND ANTI-CD20 ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 15/052966 [patent_app_country] => US [patent_app_date] => 2016-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36605 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15052966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10996378 [patent_doc_number] => 20160193316 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-07-07 [patent_title] => 'Inducing Cellular Immune Responses to Plasmodium Falciparum Using Peptide and Nucleic Acid Compositions' [patent_app_type] => utility [patent_app_number] => 14/980150 [patent_app_country] => US [patent_app_date] => 2015-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 70977 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14980150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10735963 [patent_doc_number] => 20160082113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-24 [patent_title] => 'ALTERING A B CELL PATHOLOGY USING SELF-DERIVED ANTIGENS IN CONJUNCTION WITH SPECIFIC-BINDING CYTOREDUCTIVE AGENT' [patent_app_type] => utility [patent_app_number] => 14/955237 [patent_app_country] => US [patent_app_date] => 2015-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 29828 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14955237 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10744270 [patent_doc_number] => 20160090421 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-31 [patent_title] => 'Novel Uses' [patent_app_type] => utility [patent_app_number] => 14/878523 [patent_app_country] => US [patent_app_date] => 2015-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 10574 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14878523 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10693795 [patent_doc_number] => 20160039941 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'IMMUNOTHERAPY OF AUTOIMMUNE DISORDERS USING ANTIBODIES WHICH TARGET B-CELLS' [patent_app_type] => utility [patent_app_number] => 14/859790 [patent_app_country] => US [patent_app_date] => 2015-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7271 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14859790 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10670904 [patent_doc_number] => 20160017050 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-21 [patent_title] => 'COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH AN ANTI-VEGF' [patent_app_type] => utility [patent_app_number] => 14/857112 [patent_app_country] => US [patent_app_date] => 2015-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 13091 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 14 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14857112 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10761974 [patent_doc_number] => 20160108126 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-21 [patent_title] => 'CD20 Antibodies and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 14/856061 [patent_app_country] => US [patent_app_date] => 2015-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 69458 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14856061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10769082 [patent_doc_number] => 20160115238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-28 [patent_title] => 'CD20 Antibodies and Uses Thereof' [patent_app_type] => utility [patent_app_number] => 14/856056 [patent_app_country] => US [patent_app_date] => 2015-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 66355 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14856056 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10491260 [patent_doc_number] => 20150376281 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-31 [patent_title] => 'Use of NKG2D Inhibitors for Treating Cardiovascular and Metabolic Diseases, Such as Type 2 Diabetes' [patent_app_type] => utility [patent_app_number] => 14/850688 [patent_app_country] => US [patent_app_date] => 2015-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 25406 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14850688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10714202 [patent_doc_number] => 20160060350 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-03-03 [patent_title] => 'CYTOTOXIC ANTIBODY DIRECTED AGAINST TYPE B LYMPHOID HEMATOPOIETIC PROLIFERATIONS' [patent_app_type] => utility [patent_app_number] => 14/828177 [patent_app_country] => US [patent_app_date] => 2015-08-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 11764 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14828177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12486837 [patent_doc_number] => 09993550 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-06-12 [patent_title] => Treatment of pemphigus [patent_app_type] => utility [patent_app_number] => 14/801267 [patent_app_country] => US [patent_app_date] => 2015-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15093 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14801267 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10422597 [patent_doc_number] => 20150307609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-29 [patent_title] => 'OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/795740 [patent_app_country] => US [patent_app_date] => 2015-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 26607 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14795740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10389827 [patent_doc_number] => 20150274834 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-01 [patent_title] => 'COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH FLUDARABINE AND/OR MITOXANTRONE' [patent_app_type] => utility [patent_app_number] => 14/739278 [patent_app_country] => US [patent_app_date] => 2015-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 13184 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14739278 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11627327 [patent_doc_number] => 20170137516 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-18 [patent_title] => 'TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)' [patent_app_type] => utility [patent_app_number] => 15/318754 [patent_app_country] => US [patent_app_date] => 2015-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 6997 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15318754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11053389 [patent_doc_number] => 20160250351 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-09-01 [patent_title] => 'Treating Lymphomas' [patent_app_type] => utility [patent_app_number] => 15/030567 [patent_app_country] => US [patent_app_date] => 2015-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 9131 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15030567 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12192786 [patent_doc_number] => 09896506 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-20 [patent_title] => 'Anti-CD79B antibodies and immunoconjugates and methods of use' [patent_app_type] => utility [patent_app_number] => 14/734957 [patent_app_country] => US [patent_app_date] => 2015-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 82 [patent_no_of_words] => 122005 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 10 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14734957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10380695 [patent_doc_number] => 20150265703 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-09-24 [patent_title] => 'COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH A mTOR INHIBITOR' [patent_app_type] => utility [patent_app_number] => 14/730642 [patent_app_country] => US [patent_app_date] => 2015-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 12868 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14730642 [rel_patent_id] =>[rel_patent_doc_number] =>)